Education
About Us
Working with TipRanks
Follow Us
Immunicum AB (SE:IMMU)
:IMMU
IMMU Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr4.46 - kr11.20
Previous CloseN/A
Volume3.78K
Average Volume (3M)22.56K
Market Cap
€250.54M
Enterprise Valuekr313.66M
Total Cash (Recent Filing)kr393.36M
Total Debt (Recent Filing)kr850.00K
Price to Earnings (P/E)―
Beta0.92
Next Earnings
May 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.67
Shares Outstanding50,359,577
10 Day Avg. Volume17,980
30 Day Avg. Volume22,561
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
IMMU FAQ
What was Immunicum AB’s price range in the past 12 months?
Immunicum AB lowest stock price was kr4.46 and its highest was kr11.20 in the past 12 months.
What is Immunicum AB’s market cap?
Immunicum AB’s market cap is €250.54M.
When is Immunicum AB’s upcoming earnings report date?
Immunicum AB’s upcoming earnings report date is May 06, 2025 which is in 7 days.
How were Immunicum AB’s earnings last quarter?
Immunicum AB released its earnings results on Feb 13, 2025. The company reported -kr0.626 earnings per share for the quarter, beating the consensus estimate of -kr0.746 by kr0.12.
Is Immunicum AB overvalued?
According to Wall Street analysts Immunicum AB’s price is currently Overvalued.
Does Immunicum AB pay dividends?
Immunicum AB does not currently pay dividends.
What is Immunicum AB’s EPS estimate?
Immunicum AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunicum AB have?
Immunicum AB has 50,359,577 shares outstanding.
What happened to Immunicum AB’s price movement after its last earnings report?
Immunicum AB reported an EPS of -kr0.626 in its last earnings report, beating expectations of -kr0.746. Following the earnings report the stock price went down -1.935%.
Which hedge fund is a major shareholder of Immunicum AB?
Currently, no hedge funds are holding shares in SE:IMMU
---
Company Description
Immunicum AB
Immunicum AB is a biopharmaceutical company. It develops immune therapies against a range of solid tumors. The company's lead product, ilixadencel, has been developed to be able to take advantage of each patient's own tumor antigen. Immunicum's business currently consists of research and development for the production of pharmaceuticals.
---
Technical Analysis
Xbrane Biopharma AB
―
Isofol Medical AB
―
Xintela AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
---